PMID- 34466258
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240403
IS  - 2050-0904 (Print)
IS  - 2050-0904 (Electronic)
IS  - 2050-0904 (Linking)
VI  - 9
IP  - 8
DP  - 2021 Aug
TI  - Extracorporeal Membrane Oxygenation with rituximab-combined chemotherapy in 
      AIDS-associated primary cardiac lymphoma: A case report.
PG  - e04704
LID - 10.1002/ccr3.4704 [doi]
LID - e04704
AB  - Although effective combination of antiretroviral medications is being developed, 
      the incidence of non-Hodgkin lymphoma (NHL) with human immunodeficiency/acquired 
      immunodeficiency syndrome (HIV/AIDS) still remains significantly higher than that 
      in individuals without infection. Primary cardiac lymphoma (PCL) is an NHL that 
      involves the heart and/or the pericardium. PCL is very rare and often causes 
      serious complications, which can be a diagnostic challenge. To our knowledge, no 
      study has reported the measurement of rituximab concentration under venoarterial 
      extracorporeal membrane oxygenation (VA-ECMO). Herein, we report the case of a 
      54-year-old male patient with AIDS-associated primary cardiac NHL who developed 
      right ventricular outflow tract obstruction. The patient experienced fatigue and 
      dyspnea on exertion. Contrast-enhanced computed tomography showed a bulky tumor 
      mass in his right atrium and ventricle, and an echocardiogram revealed severe 
      hypokinesis of his heart and poor cardiac output. A biopsy was performed, and 
      immunohistochemistry revealed diffuse large B-cell lymphoma. Therefore, he was 
      treated with rituximab-combined chemotherapy under VA-ECMO. Blood levels of 
      rituximab were measured during chemotherapy with VA-ECMO. Thereafter, he was 
      temporarily discharged from the hospital. This clinical case suggests that 
      VA-ECMO and rituximab-combined chemotherapy are useful in rescuing patients with 
      severe cardiopulmonary failure due to AIDS-associated PCL.
CI  - (c) 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
FAU - Fuseya, Hoyuri
AU  - Fuseya H
AD  - Department of Hematology Osaka City General Hospital Osaka Japan.
FAU - Yoshimura, Takuro
AU  - Yoshimura T
AUID- ORCID: 0000-0002-9411-4556
AD  - Department of Hematology Osaka City General Hospital Osaka Japan.
FAU - Tsutsumi, Minako
AU  - Tsutsumi M
AD  - Department of Hematology Osaka City General Hospital Osaka Japan.
FAU - Nakaya, Yosuke
AU  - Nakaya Y
AD  - Department of Hematology Osaka City General Hospital Osaka Japan.
FAU - Horiuchi, Mirei
AU  - Horiuchi M
AD  - Department of Hematology Osaka City General Hospital Osaka Japan.
FAU - Yoshida, Masahiro
AU  - Yoshida M
AD  - Department of Hematology Osaka City General Hospital Osaka Japan.
FAU - Hayashi, Yoshiki
AU  - Hayashi Y
AD  - Department of Hematology Osaka City General Hospital Osaka Japan.
FAU - Nakao, Takafumi
AU  - Nakao T
AD  - Department of Hematology Osaka City General Hospital Osaka Japan.
FAU - Inoue, Takeshi
AU  - Inoue T
AD  - Department of Pathology Osaka City General Hospital Osaka Japan.
FAU - Yamane, Takahisa
AU  - Yamane T
AD  - Department of Hematology Osaka City General Hospital Osaka Japan.
LA  - eng
PT  - Case Reports
DEP - 20210824
PL  - England
TA  - Clin Case Rep
JT  - Clinical case reports
JID - 101620385
PMC - PMC8385253
OTO - NOTNLM
OT  - acquired immune deficiency syndrome (AIDS)
OT  - diffuse large B-cell lymphoma (DLBCL)
OT  - extracorporeal membrane oxygenation (ECMO)
OT  - primary cardiac lymphoma (PCL)
OT  - rituximab
COIS- Not applicable.
EDAT- 2021/09/02 06:00
MHDA- 2021/09/02 06:01
PMCR- 2021/08/24
CRDT- 2021/09/01 07:24
PHST- 2020/11/17 00:00 [received]
PHST- 2021/07/07 00:00 [revised]
PHST- 2021/07/30 00:00 [accepted]
PHST- 2021/09/01 07:24 [entrez]
PHST- 2021/09/02 06:00 [pubmed]
PHST- 2021/09/02 06:01 [medline]
PHST- 2021/08/24 00:00 [pmc-release]
AID - CCR34704 [pii]
AID - 10.1002/ccr3.4704 [doi]
PST - epublish
SO  - Clin Case Rep. 2021 Aug 24;9(8):e04704. doi: 10.1002/ccr3.4704. eCollection 2021 
      Aug.